Holen Sie sich die Stockscreener-App
3.70
3.06%
0.11
Schlusskurs vom Vortag:
$3.59
Offen:
$3.58
24-Stunden-Volumen:
1.43M
Relative Volume:
0.29
Marktkapitalisierung:
$1.11B
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-7.1154
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
+6.94%
1M Leistung:
-5.37%
6M Leistung:
+47.41%
1J Leistung:
+25.42%
1-Tages-Spanne:
$3.51
$3.70
1-Wochen-Bereich:
$3.44
$3.74
52-Wochen-Spanne:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Vergleichen Sie ABCL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.6956 | 1.07B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - BioSpace
AbCellera Biologics’ Earnings Call: Key Insights - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Nasdaq Today Biotech Pioneer - Kalkine Media
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Insider Monkey
Published on: 2025-12-04 02:33:18 - Newser
ABCL: Advancing a differentiated internal pipeline with strong capital support and end-to-end integration - TradingView
Can AbCellera Biologics Inc. (8QQ) stock resist broad market declines2025 Momentum Check & Safe Capital Preservation Plans - Newser
What dividend safety rating applies to AbCellera Biologics Inc. (8QQ) stock2025 Trade Ideas & Fast Gain Stock Tips - Newser
What makes AbCellera Biologics Inc. (8QQ) stock appealing to growth investorsPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
9 Best Up and Coming Canadian Stocks to Buy - Insider Monkey
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN
Will AbCellera Biologics Inc. stock benefit from sector rotationJuly 2025 Short Interest & Breakout Confirmation Trade Signals - Newser
Published on: 2025-11-29 10:31:39 - earlytimes.in
AbCellera Biologics to change independent auditor after 2025 annual report By Investing.com - Investing.com Nigeria
AbCellera Biologics to change independent auditor after 2025 annual report - Investing.com
Insider Spends US$178k Buying More Shares In AbCellera Biologics - Yahoo Finance
Why AbCellera Biologics Inc. stock could rally in 2025July 2025 Final Week & Weekly Breakout Watchlists - BỘ NỘI VỤ
AbCellera biologics director Montalbano buys $178k in shares By Investing.com - Investing.com Nigeria
AbCellera biologics director Montalbano buys $178k in shares - Investing.com
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss - Insider Monkey
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How AbCellera Biologics Inc. (8QQ) stock correlates with oil marketsJuly 2025 Price Swings & Expert Curated Trade Setups - newser.com
Is AbCellera Biologics Inc. (8QQ) stock safe for risk averse investors2025 Fundamental Recap & AI Driven Stock Reports - newser.com
How AbCellera Biologics Inc. (8QQ) stock compares with market leadersJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Will AbCellera Biologics Inc. (8QQ) stock outperform energy sector in 2025Market Trend Summary & High Conviction Buy Zone Alerts - newser.com
How AbCellera Biologics Inc. (8QQ) stock reacts to weak economy2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Is AbCellera Biologics Inc. (8QQ) stock at risk of policy regulationJobs Report & Daily Entry Point Alerts - newser.com
How AbCellera Biologics Inc. stock reacts to Fed rate cutsAnalyst Upgrade & Expert Curated Trade Setups - newser.com
Is a relief rally coming for AbCellera Biologics Inc. holdersDollar Strength & Fast Gain Stock Trading Tips - newser.com
What’s next for AbCellera Biologics Inc. stock priceQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Will AbCellera Biologics Inc. stock reach Wall Street targetsWeekly Risk Report & Free Risk Controlled Daily Trade Plans - newser.com
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):